Pancreatitis markets projected to grow significantly through 2030

The global markets for acute and chronic pancreatitis are projected to see significant growth through 2030. The acute pancreatitis market is expected to rise from $6.29 billion in 2025 to $85.5 billion by 2030, driven by rising healthcare costs and the complexities of treating complications like organ failure and infection.

Simultaneously, the chronic pancreatitis market is forecasted to grow from $5.23 billion in 2025 to $70.5 billion by 2030. Key drivers for this sector include the need for enzyme replacement therapies to manage impaired digestion and the impact of lifestyle factors such as alcohol consumption.

Recent industry developments include the merger of CalciMedica and Graybug Vision to advance treatments for inflammatory diseases, and First Wave BioPharma’s progress with adlipase, a recombinant lipase for treating pancreatic insufficiency. Diagnostic advancements, such as IDEXX’s rapid pancreatic lipase test, are also supporting earlier detection and management.